致癌KRAS通过突变p53招募转录网络驱动胰腺癌转移
胰腺导管腺癌(PDAC)中致癌KRAS突变率95%,约70%患者伴TP53错义突变。研究发现致癌KRAS效应器激活CREB1,与突变p53物理互作,超激活促转移转录网络,上调FOXA1并促进WNT/β-catenin信号,驱动PDAC转移;药物抑制CREB1可降低FOXA1和β-catenin表达并减弱转移。
要点
- 致癌KRAS效应器激活CREB1,与突变p53结合形成协同节点。
- 突变p53与CREB1上调FOXA1并激活WNT/β-catenin信号促进转移。
- 药物抑制CREB1可降低FOXA1和β-catenin表达并减弱PDAC转移。
核心结论
- 致癌KRAS效应器与突变p53通过CREB1形成物理互作,超激活促转移转录网络驱动PDAC转移。
- 药物抑制CREB1可减弱PDAC转移,提示靶向该协同节点是潜在治疗策略。
研究设计与样本
- 研究基于PDAC中致癌KRAS突变率95%、TP53突变约70%的背景,探讨KRAS效应器与突变p53的直接协同。
主要发现
- 致癌KRAS效应器激活CREB1,使其与突变p53发生物理互作。
- 突变p53与CREB1上调FOXA1,激活其转录网络并促进WNT/β-catenin信号。
- 药物抑制CREB1显著降低FOXA1和β-catenin表达并减弱PDAC转移。
临床怎么用
- 靶向CREB1以破坏致癌KRAS与突变p53的协同,可能成为减轻PDAC转移的新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic ductal adenocarcinoma (PDAC) is almost uniformly fatal and characterized by early metastasis. Oncogenic KRAS mutations prevail in 95% of PDAC tumors and co-occur with genetic alterations in the TP53 tumor suppressor in nearly 70% of patients. Most TP53 alterations are missense mutations that exhibit gain-of-function phenotypes that include increased invasiveness and metastasis, yet the extent of direct cooperation between KRAS effectors and mutant p53 remains largely undefined. We show that oncogenic KRAS effectors activate CREB1 to allow physical interactions with mutant p53 that hyperactivate multiple prometastatic transcriptional networks. Specifically, mutant p53 and CREB1 upregulate the prometastatic, pioneer transcription factor FOXA1, activating its transcriptional network while promoting WNT/β-catenin signaling, together driving PDAC metastasis. Pharmacologic CREB1 inhibition dramatically reduced FOXA1 and β-catenin expression and dampened PDAC metastasis, identifying a new therapeutic strategy to disrupt cooperation between oncogenic KRAS and mutant p53 to mitigate metastasis. SIGNIFICANCE: Oncogenic KRAS and mutant p53 are the most commonly mutated oncogene and tumor suppressor gene in human cancers, yet direct interactions between these genetic drivers remain undefined. We identified a cooperative node between oncogenic KRAS effectors and mutant p53 that can be therapeutically targeted to undermine cooperation and mitigate metastasis.This article is highlighted in the In This Issue feature, p. 1861.
引用
- Kim MP, Li X, Deng J, et al. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discov. 2021. PMID: 33839689. doi:10.1158/2159-8290.CD-20-1228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。